Antipsychotic medication adherence: is there a difference between typical and atypical agents?
about
sameAs
Realistic expectations of prepulse inhibition in translational models for schizophrenia research.Review of depot aripiprazole for schizophreniaFactors associated with medication adherence among patients with schizophrenia in Mekelle, Northern EthiopiaFlupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study.Approaches to improve adherence to pharmacotherapy in patients with schizophreniaThe Six-Point Dial of Treatment: A Useful Framework for Novice Therapists.Schizophrenia: current concepts and approaches to patient careAdherence to medication for the treatment of psychosis: rates and risk factors in an Ethiopian populationFactors associated with antipsychotic medication adherence in community-based patients with schizophrenia in Hong Kong: a cross sectional study.Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.Quantitative levels of aripiprazole parent drug and metabolites in urine.Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America.Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients.Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.Factors affecting treatment discontinuation and treatment outcome in patients with schizophrenia in Korea: 10-year follow-up study.Understanding antipsychotic "atypicality": a clinical and pharmacological moving targetPoor response to treatment: beyond medication.Psychosocial interventions and medication adherence in bipolar disorderBaseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety studyRelapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychoticsAn update of safety of clinically used atypical antipsychotics.Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychoticsA review of pharmacologic strategies for switching to atypical antipsychoticsOutpatient Follow-Up Visit after Hospital Discharge Lowers Risk of Rehospitalization in Patients with Schizophrenia: A Nationwide Population-Based StudyIdentifying and improving non-adherence in bipolar disorders.Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians' perceptions of adherence vs. pharmacy claims.Educational interventions for mental health consumers receiving psychotropic medication: a review of the evidence.The impact of subjective well-being under neuroleptic treatment on compliance and remission.Defining and assessing adherence to oral antipsychotics: a review of the literatureCurrent schizophrenia drugs: efficacy and side effects.Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.The relationship between patient satisfaction and treatment outcomes in schizophrenia.Improving patient outcomes in schizophrenia: achieving remission.The case for long-acting antipsychotic agents in the post-CATIE era.Differential diagnoses and management strategies in patients with schizophrenia and bipolar disorderPersistence of Antipsychotic Treatment in Elderly Dementia Patients: A Retrospective, Population-Based Cohort Study.Health diaries for self-monitoring and self-regulation: applications to individuals with serious mental illness.Risperidone long-acting injection: a review of its long term safety and efficacy.Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective DisorderThe use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.
P2860
Q24645703-8630CE17-6EF0-4DD8-8716-4B11D12B4BF2Q27008464-554F11C5-7293-4700-859C-08DE6F304E15Q28545127-2DEF0756-A9F8-4A55-8A88-A9559B3AE66FQ30654033-A0CB945C-82FD-43C4-B9B2-B875A942DB54Q33645198-CEAA3B4B-AE94-44D6-9218-D79692D943E2Q33920656-BECE1891-86F3-4441-9713-FE30078DB4BDQ33932520-2D22FDCB-FAC0-4A51-A071-0579DE7A9DAAQ34308009-1E23A549-88DE-4A15-90AE-CFAAD708F8ADQ34318836-332275DA-6EBE-467C-800B-D9DC693E351DQ34386881-68FB2946-25D3-4F09-AE0D-2ABEC9CFD441Q34459567-2027713C-C485-41B1-A148-CC78DAC94964Q34560335-2EA3D752-A36D-476B-8617-8A608275CB54Q34576439-854A4113-2E43-43E5-88D6-1DE8A4913F4EQ34660553-263004AE-8089-4B31-89EA-D27AF5D3B1A3Q34811937-BD4E6D6A-A8BD-475F-B492-3F15EF8B47A6Q35200831-9479BA8B-8AAC-4BB3-AE97-0D2E50FAF4DCQ35236765-B4160FCD-8D8F-4BE6-BAB3-D380AA0DB0E2Q35236962-07B1C6F3-5F9F-49CE-9C9A-4846ED2850C3Q35841195-F29F2938-A7DB-4E40-8F3E-81A5EA334039Q35873789-743E763C-9C46-40B2-8ECD-8ED1A2BFC2FEQ36062184-4E26F55C-0480-4A43-8CD0-CEF3165E46C5Q36121675-87C5F7E0-4FD2-439A-B355-B4FBCA4EC920Q36199687-9970C928-B830-49C8-804B-FA3BC5ADB0A9Q36205371-95268854-5F98-4E65-B334-F9F888B9F80AQ36286408-A07113AC-EC7B-4AAC-A866-D06AAAEA226AQ36371461-235589DF-57EC-43AB-ADCE-BC521A856CF1Q36405653-9238BFC4-B509-4F73-B5F7-1369E63A51B0Q36460707-F8464A65-2F4A-447C-ADB1-FE2FF0F64B85Q36481418-37A68CCA-C89E-4BC8-BDF6-9E59A740D428Q36488206-21591A76-7F48-421B-B4D1-C43BE51432B4Q36626247-0CD74C98-EB20-4E73-A7C2-E9F2A51E9CAAQ36626251-3F546EEE-F5DC-4612-88E9-D3FD9D320CD5Q36626254-DFB4F57E-1B96-4F03-B89D-4094AE31BA3EQ36758680-DC5FA8D2-CEED-4EDD-AB66-EB2FA24E7BB4Q36836740-86D108F2-6763-4368-AD0C-38C44B2A3C6BQ37022906-80930C7B-61B0-4C43-8E9B-39EDE069E508Q37024004-BC9A6784-439E-4833-B5A4-F2BC5CEED44FQ37062563-0C057913-B75C-4461-A124-D051E68237CCQ37063242-4ABB532A-A5C0-4210-995C-796EF7AB74BCQ37076300-70BCF7C2-76E2-4CD1-9B6B-EB4279E48316
P2860
Antipsychotic medication adherence: is there a difference between typical and atypical agents?
description
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2002
@ast
im Januar 2002 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 2002)
@en
vedecký článok (publikovaný 2002-01)
@sk
vědecký článek publikovaný v roce 2002
@cs
wetenschappelijk artikel (gepubliceerd in 2002-01)
@nl
наукова стаття, опублікована в січні 2002
@uk
مقالة علمية (نشرت عام 2002)
@ar
name
Antipsychotic medication adher ...... n typical and atypical agents?
@ast
Antipsychotic medication adher ...... n typical and atypical agents?
@en
Antipsychotic medication adher ...... n typical and atypical agents?
@nl
type
label
Antipsychotic medication adher ...... n typical and atypical agents?
@ast
Antipsychotic medication adher ...... n typical and atypical agents?
@en
Antipsychotic medication adher ...... n typical and atypical agents?
@nl
prefLabel
Antipsychotic medication adher ...... n typical and atypical agents?
@ast
Antipsychotic medication adher ...... n typical and atypical agents?
@en
Antipsychotic medication adher ...... n typical and atypical agents?
@nl
P2093
P3181
P1476
Antipsychotic medication adher ...... n typical and atypical agents?
@en
P2093
Christian R Dolder
Jonathan P Lacro
Laura B Dunn
P3181
P356
10.1176/APPI.AJP.159.1.103
P407
P577
2002-01-01T00:00:00Z